Correction for 'Correction: Hypoxia inducible factor (HIF) as a model for studying inhibition of proteinprotein interactions' by George M. Burslem et al., Chem. Sci., 2017, 8, 5214-5215. The authors regret that in their original correction regarding Fig. 3 there remained errors in the structures of EZN-2208, geldanamycin, ganetespib and echinomycin. The correct gure is displayed below.
Modulators of the HIF pathway (a) topotecan and derivative EZN-2208 (b) 2-oxoglutarate (c) DMOG and oxalyl glycine (d) FG-2216 (e) roxadustat (f) geldanamycin (g) ganetespib (h) X-ray crystal structure of a hydroxyproline derived inhibitor (orange) bound to pVHL (cyan), PDB ID 3zrc (i) optimised hydroxyproline derived pVHL inhibitor VH298 (j) echinomycin (k) DNA sequence specific polyamide (l) bortezomib.
